NCT07292272

Brief Summary

Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
180

participants targeted

Target at P75+ for not_applicable

Timeline
81mo left

Started Apr 2026

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
Apr 2026Mar 2033

First Submitted

Initial submission to the registry

December 5, 2025

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 18, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

April 9, 2026

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 25, 2032

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 25, 2033

Last Updated

July 1, 2026

Status Verified

December 1, 2025

Enrollment Period

6 years

First QC Date

December 5, 2025

Last Update Submit

June 29, 2026

Conditions

Keywords

Hodgkin LymphomaLeukemiaLymphoid LeukemiaMultiple MyelomaMyeloid LeukemiaMonocytic LeukemiaNon-hodgkin LymphomaOther Hematologic ConditionEpigenetic clockBiological agingQuality of lifeBlood cancer survivors

Outcome Measures

Primary Outcomes (2)

  • Percentage of participants who adhered to the exercise regimen at 6-months post enrollment.

    Participants achieving at least 120 minutes per week of moderate-intensity aerobic exercise, measured using Polar heart rate monitor data and exercise diaries.

    6 Months from start of program

  • Percentage of participants who adhered to the exercise regimen at 12-months post enrollment.

    Participants achieving at least 120 minutes per week of moderate-intensity aerobic exercise, measured using Polar heart rate monitor data and exercise diaries to assess sustainability of adherence.

    12 Months from start of program.

Secondary Outcomes (1)

  • Physical Function (6- Minute Walk Test Distance)

    6 months from randomization

Other Outcomes (7)

  • Physical Function Maximal Oxygen Consumption (VO₂ max)

    6 months from randomization

  • Neuro-QOL Cognition Function Short Form Score

    6 months from randomization

  • Trail Making Test Performance

    6 months from randomization

  • +4 more other outcomes

Study Arms (2)

Intervention Arm: Exercise + Behavioral Coaching

EXPERIMENTAL

Intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence

Behavioral: Behavioral Coaching InterventionBehavioral: Virtual Exercise Platform

Enhanced Usual Care-Virtual Gym

ACTIVE COMPARATOR

Participants will receive access to a virtual exercise platform, and educational sessions but will not receive behavioral coaching

Behavioral: Virtual Exercise Platform

Interventions

Intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence

Intervention Arm: Exercise + Behavioral Coaching

Access to a virtual exercise platform that provides exercise classes and educational sessions for older survivors of blood cancer

Enhanced Usual Care-Virtual GymIntervention Arm: Exercise + Behavioral Coaching

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥50 years
  • A history of hematological malignancy
  • Participants must be able to and willingly give informed consent

You may not qualify if:

  • Patients receiving intensive induction or consolidation chemotherapy. Maintenance chemotherapy, or lower-intensity chemotherapy for an indolent hematological malignancy is allowed.
  • Neurodegenerative disease (e.g. Alzheimer's dementia), stroke, or uncontrolled psychotic disorders (e.g. schizophrenia or bipolar disorder) in the past 3 months if those disorders are considered significant enough to impair participation in the study.
  • Illnesses such as clinical evidence of decompensated heart failure, unstable angina, or orthopedic or neuromuscular disorders that could limit safe participation in aerobic exercise.
  • Cardiopulmonary exercise test results that preclude safe exercise (e.g., life-threatening arrhythmia, balance difficulties, peak VO2 \<10 ml/kg/min).
  • Estimated life expectancy of less than 6 months (that precludes assessment of study primary endpoint).
  • Self-reported pregnancy or the possibility of pregnancy.
  • Participants who do not plan to follow up at the participating center.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Nebraska Medical Center

Omaha, Nebraska, 68008, United States

RECRUITING

MeSH Terms

Conditions

Hematologic NeoplasmsLeukemiaLeukemia, LymphoidMultiple MyelomaLeukemia, MyeloidLeukemia, Monocytic, AcuteLymphoma, Non-HodgkinHodgkin Disease

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesNeoplasms by Histologic TypeLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesNeoplasms, Plasma CellHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHemorrhagic DisordersLeukemia, Myeloid, AcuteLymphoma

Study Officials

  • Vijaya Raj Bhatt, MBBS,MS

    University of Nebraska

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 5, 2025

First Posted

December 18, 2025

Study Start

April 9, 2026

Primary Completion (Estimated)

March 25, 2032

Study Completion (Estimated)

March 25, 2033

Last Updated

July 1, 2026

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations